FEMY · Femasys Inc. Common Stock
View on chartInsiders & Stakes
| Dyett John | ▼ Sell | Other | 290,344 Shares held | 12/15/2021 | View profile |
| Currie Daniel Scott Chief Operating Officer | ▼ Sell | Other | 86,275 Shares held | 6/2/2025 | View profile |
| Elefant Dov Chief Financial Officer | ▲ Buy | Open Market | 15,625 Shares held | 8/7/2026 | View profile |
| Lee-Sepsick Kathy Chief Executive Officer | ▲ Buy | Open Market | 15,625 Shares held | 8/7/2026 | View profile |
| Witte William Benson | ▼ Sell | Other | 12,191 Shares held | 12/15/2021 | View profile |
| Canning John Charles Chief Operating Officer | ▲ Buy | Open Market | 4,375 Shares held | 8/7/2026 | View profile |
| Mifek Jeffrey Gerald Chief Clinical-Medical Affairs | ▲ Buy | Open Market | 3,125 Shares held | 8/7/2026 | View profile |
| Sipos Jeremy Alexander Chief Technology Officer | ▲ Buy | Open Market | 3,125 Shares held | 8/7/2026 | View profile |
| Larsen Charles | ▼ Sell | Other | 56 Shares held | 6/2/2025 | View profile |
Transaction History
| Sipos Jeremy Alexander | ▲ Buy | Open Market | 3,125 | $10K | 8/7/2026 |
| Elefant Dov | ▲ Buy | Open Market | 15,625 | $50K | 8/7/2026 |
| Lee-Sepsick Kathy | ▲ Buy | Open Market | 15,625 | $50K | 8/7/2026 |
| Canning John Charles | ▲ Buy | Open Market | 4,375 | $14K | 8/7/2026 |
| Mifek Jeffrey Gerald | ▲ Buy | Open Market | 3,125 | $10K | 8/7/2026 |
| Lee-Sepsick Kathy | ▼ Sell | Other | 48,535 | — | 8/27/2025 |
| Elefant Dov | ▼ Sell | Other | 38,828 | — | 8/27/2025 |
| Larsen Charles | ▼ Sell | Other | 24,510 | $25K | 6/2/2025 |
| Currie Daniel Scott | ▼ Sell | Other | 19,608 | $20K | 6/2/2025 |
| Elefant Dov | ▼ Sell | Other | 19,608 | $20K | 6/2/2025 |
| Lee-Sepsick Kathy | ▼ Sell | Other | 34,314 | $35K | 6/2/2025 |
| Dyett John | ▼ Sell | Other | 3,219,795 | $0 | 12/15/2021 |
| Dyett John | ▼ Sell | Other | 175,635 | $0 | 12/15/2021 |
| Witte William Benson | ▼ Sell | Other | 12,191 | $0 | 12/15/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Femasys to Showcase FemaSeed at ASRM 2026
Femasys announced it will exhibit its FemaSeed fertility treatment at the ASRM 2026 Scientific Congress & Expo. This move signals an expansion of the company's commercialization strategy as it seeks to increase visibility for its product. The stock currently trades near its 52-week low, with an RSI of 36.7 indicating recent weakness.
Femasys to Showcase FemaSeed at ASRM 2026. Femasys announced it will exhibit its FemaSeed fertility treatment at the ASRM 2026 Scientific Congress & Expo. This move signals an expansion of the company's commercialization strategy as it seeks to increase visibility for its product. The stock currently trades near its 52-week low, with an RSI of 36.7 indicating recent weakness.